Evidence map›Paper›PMID 38180827›Full record

ArticleNucleic acids research2024

Kaposi's sarcoma herpesvirus exploits the DNA damage response to circularize its genome.

Shijun Li, Bing Liu, Min Tan, Franceline Juillard, Agnieszka Szymula, Ángel L Álvarez, Nicholas Van Sciver, Athira George, Akshaya Ramachandran, Komal Raina and 4 more

Open access · goldAbstract read
In one paragraph

Article in Nucleic acids research, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.4field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 5 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 3 institutions in 2 countries.

Shijun LiDepartments of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA 02115, USA.
Bing LiuDepartments of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA 02115, USA.
Min TanDepartments of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA 02115, USA.
Franceline JuillardDepartments of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA 02115, USA.
Agnieszka SzymulaDepartments of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA 02115, USA.
Ángel L ÁlvarezDepartments of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA 02115, USA.ORCID 0000-0001-9388-8595
Nicholas Van SciverDepartments of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA 02115, USA.
Athira GeorgeDepartments of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA 02115, USA.
Akshaya RamachandranDepartments of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA 02115, USA.
Komal RainaDepartments of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA 02115, USA.
Vinayak Sadasivam TumuluriDepartments of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA 02115, USA.
Catarina N CostaInstituto de Medicina Molecular, Faculdade de Medicina, Universidade de Lisboa, Avenida Professor Egas Moniz, 1649-028 Lisboa, Portugal.
J Pedro SimasInstituto de Medicina Molecular, Faculdade de Medicina, Universidade de Lisboa, Avenida Professor Egas Moniz, 1649-028 Lisboa, Portugal.
Kenneth M KayeDepartments of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA 02115, USA.ORCID 0000-0001-5802-4556
Brigham and Women's Hospital · USUniversity of Lisbon · PTBroad Institute · US

Funding

MOLECULAR BASIS OF VIRAL INFECTIVITYT32AI007245 · NIAID · HARVARD UNIVERSITY (MEDICAL SCHOOL) · PI Aaron Gregory Schmidt · 1985 to 2026
$11.3M
KSHV Latent Infection ReplicationR01DE025208 · NIDCR · BRIGHAM AND WOMEN'S HOSPITAL · PI KAYE, KENNETH M · 2015 to 2025
$5.3M
KSHV Latency RegulationR01AI165382 · NIAID · BRIGHAM AND WOMEN'S HOSPITAL · PI Kenneth M Kaye · 2022 to 2026
$3.5M
Genetic and Biochemical Studies of KSHV LANAR01AI150575 · NIAID · BRIGHAM AND WOMEN'S HOSPITAL · PI KAYE, KENNETH M · 2020 to 2024
$3.4M
NIAID NIH HHS R01 AI150575NIAID NIH HHS R01 AI165382NIAID NIH HHS T32 AI007245NIDCR NIH HHS R01 DE025208NIH HHS AI150575
6 · The paper itself

Abstract

To establish lifelong, latent infection, herpesviruses circularize their linear, double-stranded, DNA genomes through an unknown mechanism. Kaposi's sarcoma (KS) herpesvirus (KSHV), a gamma herpesvirus, is tightly linked with KS, primary effusion lymphoma, and multicentric Castleman's disease. KSHV persists in latently infected cells as a multi-copy, extrachromosomal episome. Here, we show the KSHV genome rapidly circularizes following infection, and viral protein expression is unnecessary for this process. The DNA damage response (DDR) kinases, ATM and DNA-PKcs, each exert roles, and absence of both severely compromises circularization and latency. These deficiencies were rescued by expression of ATM and DNA-PKcs, but not catalytically inactive mutants. In contrast, γH2AX did not function in KSHV circularization. The linear viral genomic ends resemble a DNA double strand break, and non-homologous DNA end joining (NHEJ) and homologous recombination (HR) reporters indicate both NHEJ and HR contribute to KSHV circularization. Last, we show, similar to KSHV, ATM and DNA-PKcs have roles in circularization of the alpha herpesvirus, herpes simplex virus-1 (HSV-1), while γH2AX does not. Therefore, the DDR mediates KSHV and HSV-1 circularization. This strategy may serve as a general herpesvirus mechanism to initiate latency, and its disruption may provide new opportunities for prevention of herpesvirus disease.

Indexed as

Herpesvirus 8, HumanSarcoma, KaposiDNADNA RepairHumansVirus LatencyDNA

Identifiers

PMID38180827
PMCPMC10899755
OpenAlexW4390618405

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.